Purpose: Lymphatic vessel endothelial hyaluronan receptor (LYVE-1), a speci c molecular marker for lymph systems, has only one known ligand, hyaluronan (HA). Many studies have reported that HA, on the surface of tumor cells, is associated with the metastatic behavior of cancer cells. e interaction of LYVE-1 with HA may facilitate tumor cell attachment and enhance dissemination of tumor cells to lymph nodes. e aim of this study was to explore the biological function of LYVE-1 and to determine whether the interaction between LYVE-1 and HA was directly involved in the adhesion of tumor cells to lymphatic vessels.
e common pathways of cancer cell dissemination are via the lymphatic system and the bloodstream. Previous studies, using various inhibitors and other approaches, have indicated that angiogenesis is important for tumor growth and hematogenous metastasis [1] [2] [3] [4] [5] [6] ; however, little is known about the role of the lymphatic system in metastasis because of a lack of speci c markers that discriminate between the lymphatics and blood vessels. Recently, the identi cation of lymphatic endothelial molecules, such as LYVE-1 [7] , Prox-1 [8] , podoplanin [9] , β-chemokine receptor [10] , and macrophage mannose receptor [11] , has provided novel tools for examining tumor lymphatic vessels.
LYVE-1, a homologue of CD44 [7] , is a cell surface receptor for hyaluronan (HA) in the lymphatic endothelium. Previous studies in breast cancer cell lines suggested that a high density of lymph vessels expressing LYVE-1 correlated with a high frequency of regional lymph node metastases [12, 13] . LYVE-1 is one of the most speci c lymphatic markers and much attention has been paid to its role in tumor lymphangiogenesis and metastasis; however, its biological function has not been extensively studied. Over-expression of HA has been associated with cancer metastasis [14, 15] , and LYVE-1, which is expressed only in the lymphatic endothelium, may be involved in cancer cell metastasis through binding to HA on the cell surface. Nevertheless, there has been no evidence that LYVE-1 is involved in the transport of tumor cells by lymph vessels.
In this study, the biological role of LYVE-1 in cancer metastasis was investigated. e LYVE-1 gene was cloned and coexpressed with the green uorescent protein (GFP) in COS-7 cells. To observe the adhesion reaction of LYVE-1 with HA on the tumor surface, three measurements were made: 1) LYVE-1 protein expression on COS-7 cells, 2) HA expression on the surface of HS-578T cells, and 3) binding of HS-578T cells, before and a er treatment with Streptomyces hyaluronidase, to COS-7 LYVE-1(+) , COS-7 pEGFP-N1 and COS-7 cells. e results showed that LYVE-1, which was expressed in COS-7 cells, could bind exogenously added hyaluronan and could enhance the adhesion capability of COS-7 cells to HS-578T cells by binding the HA on the surface of the HS-578T cells.
Materials and Methods
PrimeSTAR HS DNA Polymerase, T4 DNA Ligase, HindIII and EcoRI restriction enzymes were purchased from Takara Biotechnology Co., Ltd. (Dalian, China). A pair of PCR primers speci c for LYVE-1 was designed according to the published human LYVE-1 cDNA sequence (GenBank AF118108) and synthesized by Invitrogen LifeTechnologies (CA, USA). Plasmids containing full-length human LYVE-1 cDNA and pEGFP-N1 were constructed in our laboratory. A polyclonal antibody against human LYVE-1 (goat anti-human) and a Cy3-donkey anti-goat antibody were purchased from Santa Cruz Biotechnology, Inc. (CA, USA). DMEM was purchased from Gibco (CA, USA). Fetal bovine serum (FBS) was from Hyclone (Lanzhou, China). Streptomyces hyaluronidase, chemicals, and other reagents were from Sigma (MO, USA).
Mammalian cells (simian virus 40-transformed African Green monkey kidney cell line COS-7) and breast cancer cells (HS-578T) were purchased from the cell bank at Shanghai Institute of Cell Biology. Cells were cultured in Dulbecco's modi ed Eagle's medium (DMEM) (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin and 100 U/ml streptomycin, and they were maintained at 37°C in a humidi ed atmosphere of 5% CO2.
For cell surface expression of full-length LYVE-1, the entire LYVE-1 coding sequence was reampli ed (94 0 C for 1 min, 55 0 C for 1 min and 72 0 C for 1 min; 30 cycles) from the original clone with the primers LYVE-1 F HindIII (GTA-CAAGCTTG CCG CCACCATG G CCAG GTG CT T CAGCC) and LYVE-1 R EcoRI (GTCAGAATTCCAAC TTCAGCTTCCAGGC) using PrimeSTAR HS DNA Polymerase. A er digestion with HindIII and EcoRI, the PCR product was ligated into a HindIII/ EcoRI digested pEGFP-N1 vector.
e pEGFP-N1 construct was transfected into COS-7 cells using lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
For detection of LYVE-1 protein expression in transfected COS-7 cells and HS-578T cells, cell lysates were boiled in SDS-PAGE sample bu er, electrophoresed on 10% polyacrylamide SDS-PAGE gels and transferred to polyvinylidene uoride (PVDF) membranes. Blots were incubated with a LYVE-1 polyclonal antibody (1:1000 dilution in TBS, pH 7.5 with 5% dried milk powder and 0.1% Tween 20) and developed with donkey anti-goat IgG-HRP using chemiluminescent detection (Pierce ECL kit; ermo Scienti c, IL, USA). Texas red-labeled HA (TR-HA) was prepared according to published methods [16] . To detect the binding of COS-7 membrane-expressed LYVE-1 to HA, COS-7 LYVE-1(+) , COS-7 pEGFP-N1 , and COS-7 cells were plated in 24-well plates in DMEM supplemented with 10% FCS. e cells were then exposed to 200 μg TR-HA conjugate in 1 ml of medium for varying durations (30 min to 12 h), rinsed twice in cold PBS, and xed in a solution of 2% paraformaldehyde in PBS for 10 min at room temperature. Cells were then washed three times for 5 min each in PBS, and viewed using an OLYMPUS IX70 inverted phase-contrast microscope ( Japan).
Visualization and morphometric analysis of HA matrices were done using a particle-exclusion assay as previously described [17, 18] . Brie y, 1x10 5 HS-578T cells and COS-7 cells were separately plated in 35 mm tissue culture dishes in DMEM containing 10% FBS. A er 24 hours, 750 μl of a suspension of xed and washed human erythrocytes (≈10 8 /ml) were added to the cells and allowed to settle for 15 minutes. e HA-speci c Streptomyces hyaluronidase was then added at a concentration of 1 U/ml of medium. HA matrices were visualized before and a er digestion of HA using an OLYMPUS IX70 inverted phase-contrast microscope.
Adhesion of HS-578T cells to COS-7 cells was measured as previously described [19] . Brie y, COS-7 LYVE-1(+) , COS-7 pEGFP-N1 , and COS-7 cells were isotopically grown to con uent monolayers on glass coverslips in 24-well plates and maintained in DMEM supplemented with 10% FBS. HS-578T cells pre-incubated with DAPI (Roche, Switzerland) (50 μg/ml, 37°C, 5 min) were harvested with 0.02% EDTA, and 300 μl of cell suspension (5 × 10 4 cells/well) treated with control medium or with 30 U/ml of Streptomyces hyaluronidase were added to the monolayer of COS-7 cells and incubated at 37°C for 15 min under normal conditions. Co-cultured cells were then gently washed three times with adhesion bu er containing DMEM supplemented with 0.1% BSA and xed in 4% glutaraldehyde in PBS for counting the number of bound tumor cells.
Results
A full-length human LYVE-1 cDNA was successfully amplied. e product was cloned into a pEGFP-N1 vector. e LYVE-1 cDNA construct was sequenced and proven to be the same as human LYVE-1 (GenBank AF118108). Colony selection was carried out using plasmid and LYVE-1 primers. e extracted plasmid (Fig. 1A , lane 2) was subsequently digested using EcoRI and HindIII enzymes, which demonstrated that the plasmid insert was the correct size (Fig. 1A, lane 3 ). e expression level of LYVE-1 protein in the transfected cells was di erent from that in HS-578T cells (Fig. 1B C) .
Consistent with the previous characterization of the COS-7 cell line, COS-7 cells themselves and GFP control transfectants did not yield detectable amounts of LYVE-1 product (lanes 1 and 2 respectively). COS-7 cells were considered naked cells, since few HA binding molecules were detected on their surface. Using a polyclonal antibody, Western blotting of the COS-7 LYVE-1(+) cells revealed a major band that migrated with an apparent molecular mass of 70 KD. LYVE-1 expression was not detected in HS-578T cells (Fig. 1C) .
To further con rm the identi cation of the LYVE-1 molecule as an integral membrane glycoprotein, COS-7 cells were transiently transfected with vector alone (pEGFP-N1) or with vector containing full-length human LYVE-1 cDNA and stained with polyclonal LYVE-1 antibodies. As shown in Fig.  1D , COS-7 LYVE-1(+) cells displayed intense surface staining that is absent from both the COS-7 pEGFP-N1 cells and the nontransfected COS-7 cells.
Cells
To assess the functionality of LYVE-1, binding of TR-HA to the COS-7 LYVE-1(+) , COS-7 pEGFP-N1 and COS-7 cells was measured. As shown in Fig. 2 , the majority of LYVE-1 trans-
fectants bound TR-HA, while the control, mock-transfected cells did not. ese results provided clear evidence that the LYVE-1 in COS-7 cells interacted with HA.
A particle-exclusion assay [20] was used to determine if human HS-578T cells or COS-7 cells were capable of producing and organizing HA-rich pericellular matrices. In this assay, HS-578T cells displayed a wide pericellular space that excluded xed erythrocytes (Fig. 3A) . Streptomyces hyaluronidase gradually removed the HA layer on the plasma membrane, and erythrocytes approached the cell body, leading to the disappearance of the exclusion space (Fig. 3B) : these data are consistent with previous work [17] . Our results showed that COS-7 cells, having low capacity for HA production, could not exclude the xed erythrocytes (Fig. 3C) , and almost no change was observed a er adding hyaluronidase.
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Clin In E48 (Fig. 4) . In addition, pretreatment of HS-578T cells with Streptomyces hyaluronidase decreased the adhesion to COS-7 LYVE-1(+) cells FIGURE 5 NEAR HERE (Fig. 5) . ese results demonstrated that LYVE-1 may contribute to the adhesion of HS-578T cells to COS-7 cells, which might be partly mediated by HA.
Discussion is study suggests a role for LYVE-1 in the regulation of adhesion of tumor cells to COS-7 cells
When COS-7 cells were transfected with LYVE-1, a rapid and signi cant change was observed in the adherence of COS-7 LYVE-1(+) cells with a high HA expressing breast cancer cell line, HS-578T, while the COS-7 pEGFP-N1 cells or the parental nontransfected COS-7 cells, did not exhibit this alteration under similar conditions. is adhesion could be partially inhibited by a brief treatment with Streptomyces hyaluronidase, an enzyme that speci cally degraded hyaluronan. ese ndings suggest that
Clin In E49 LYVE-1, speci cally located in the lymph vessels, is involved in the adhesion of tumor cells to COS-7 cells through binding HA on the tumor cell surface.
Breast cancer is a common cancer a ecting women [21] . It spreads primarily via the lymphatics, but the mechanism by which tumor cells enter, interact with, and transport within lymphatic vessels is poorly understood due to the lack of speci c markers for the lymphatic endothelium. e development of speci c markers, such as the lymphatic hyaluronan receptor LYVE-1, has allowed many new experimental studies of tumor lymphatics to be initiated [22, 23] , and has expanded the study of tumor metastasis since the blood vasculature has been the primary system studied in metastasis.
Tumor cell arrest and the formation of stable adhesive interactions between tumor cells and endothelial cells are crucial steps in the metastatic process. Our hypothesis was that LYVE-1, through interaction with HA on the tumor cell surface, could in uence the adhesion of tumor cells to lymphatic endothelial cells and allow the tumor cells to metastasize into the lymph systems or be transported within the lymph vessels. Previous research indicated that LYVE-1 could not bind HA in vitro, and suggested that LYVE-1, like CD44, may become active a er appropriate unmasking in vi o. LYVE-1, expressed on COS-7 cells, could bind HA, but, when expressed on other cells, was unable to bind HA. COS-7 cells were considered as naked cells, since few HA binding molecules are present on the cell surface to prevent the adhesion of LYVE-1. Other cells may have other HA receptors (for example, CD44) to interfere with LYVE-1.
In this study, COS-7 cells were transfected with LYVE-1 to model lymphatic endothelial cells, and COS-7 LYVE-1(+) cells were able to bind Texas Red-HA as reported. Meanwhile, the
Clin In E50 highly HA expressing breast carcinoma cell line, HS-578T, was chosen to adhere to COS-7 LYVE-1(+) , COS-7 pEGFP-N1 , and nontransfected COS-7 cells to explore the function of tumor cell adhesion to lymphatic endothelium cells, as mediated by LYVE-1. Transfection of LYVE-1 into COS-7 cells was found to promote the adhesion of HS-578T cells to COS-7 LYVE-1(+) cells, possibly by binding the HA on the tumor surface, which was consistent with the observation that LYVE-1 could bind immobilized and soluble HA [7] . We also found that Strepto myces hyaluronidase could reduce, but not prevent, the adhesion between COS-7 LYVE-1(+) cells and HS-578T cells. us, it appears that LYVE-1 mediates the adhesion of tumor cells through its surface HA. Streptomyces hyaluronidases could not prevent the adhesion by LYVE-1, which may be explained by incomplete deletion of HA on the tumor surface. Consistent with previous work by Kirsi Rilla hyaluronan and the exclusion space were reduced, but not eliminated by Streptomy ces hyaluronidases. e inability of Streptomyces hyaluronidases to completely prevent adhesion by LYVE-1 might also be explained by the ongoing synthesis of HA, making it di cult to obtain an equilibrium state. It is also possible that LYVE-1 might bind to additional ligands and additional studies are needed to explore this possibility. Moreover, previous studies have reported that LYVE-1 undergoes cytokine-induced endocytosis, independent of HA uptake, under in ammation conditions (25) . A recent study (26) suggests that HA homeostasis is unperturbed in LYVE-1 -/ -mice under normal physiological conditions. us, there may be some complicated mechanisms involved in the regulation of LYVE-1 function in vi
In conclusion, our study provides evidence that LYVE-1 has a speci c biological function and is not merely a useful tracing marker for the lymphatics. e results revealed the possible role of LYVE-1 in the mediation of the adhesion of tumor cells to lymphatic vessels by means of binding to the tumor cell surface HA. ese results suggest that LYVE-1 might represent a potential pharmacological target for the inhibition of tumor metastasis through lymph systems; however, as no experimental procedures have been explored with regard to lymphatic endothelial cells, it could not be con rmed that LYVE-1 is directly involved in the tumor cell metastasis in the lymphatic vessels. Further work in this area is ongoing in our laboratory.
